U.S. Supreme Court Temporarily Preserves Mail‑Order Abortion Pill Access as States Enact New Restrictions

In May 2026 the U.S. Supreme Court issued an emergency order that kept the Food and Drug Administration’s rule allowing the abortion medication mifepristone to be prescribed via telehealth and mailed nationwide. The Court halted a lower‑court injunction that had briefly blocked the rule, leaving the current access framework in place while the Louisiana‑v‑FDA case proceeds. Justices Samuel Alito and Clarence Thomas dissented, arguing the rule undermines state abortion bans and may violate the 1873 Comstock Act.

Pro‑life organizations responded with strong condemnation, labeling the decision a “murder‑by‑mail” policy and calling for the FDA to rescind the drug’s approval. Leaders of groups such as Live Action, the Family Research Council and the National Right to Life Committee demanded that the mailing of mifepristone be halted, citing safety concerns and state‑level protections.

Simultaneously, state legislatures moved to tighten controls. Oklahoma Governor Kevin Stitt signed House Bill 1168, creating a felony offense for anyone who knowingly traffics abortion‑inducing drugs, with penalties up to ten years in prison and $100,000 fines. In Iowa, Governor Kim Reynolds signed a package of bills that require in‑person prescribing of mifepristone and other abortion‑inducing medications, effectively ending telehealth and mail‑order access in the state as of July 1. The Iowa measures also introduce parental‑consent requirements for HPV vaccinations.

Mifepristone now accounts for roughly two‑thirds of U.S. abortions, and telehealth services have become a crucial avenue for patients in restrictive states or rural areas. The Supreme Court’s temporary preservation of mail‑order access keeps that pathway open pending further litigation, while state actions signal a growing push to curtail it.